Oncolytic virus cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines.

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Some of Oncolytic Virus Cancer Therapy Companies:

• CG Oncolgy
• Oncolytics Biotech
• Astellas Pharma
• DNAtrix
• Nouscom
• ImmVira Pharma
• Targovax
• Istari Oncology
• SillaJen Biotherapeutics
• Transgene
• Advantagene
• Wuhan Binhui Biotechnology
• PsiOxus Therapeutics
• VCN Biosciences
• Vyriad
• Oncolys Biopharma
• Replimune
• Oncorus
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

DelveInsight’s Oncolytic Virus Cancer Therapy report covers around 85+ products under different phases of clinical development like:

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Current Oncolytic Virus Cancer Therapy Scenario and Oncolytic Virus Cancer Therapy Emerging Therapies:

• How many companies are developing Oncolytic Virus Cancer Therapy drugs?
• How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Table of Contents:

Introduction

Executive Summary

Oncolytic Virus Cancer Therapy: Overview

Pipeline Therapeutics

Therapeutic Assessment

Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Oncolytic Virus Cancer Therapy Collaboration Deals

Late Stage Products (Phase III) 

CG0070: CG Oncolgy

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

Pelareorep: Oncolytics Biotech

Drug profiles in the detailed report…..

Early Stage Products (Phase I) 

ASP-9801: Astellas Pharma

Pre-clinical and Discovery Stage Products

Research programme: oncolytic vaccinia virus therapies – AstraZeneca/Transgene

Inactive Products

Oncolytic Virus Cancer Therapy Key Companies

Oncolytic Virus Cancer Therapy Key Products

Oncolytic Virus Cancer Therapy- Unmet Needs

Oncolytic Virus Cancer Therapy- Market Drivers and Barriers

Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion

Oncolytic Virus Cancer Therapy Analyst Views

Oncolytic Virus Cancer Therapy Key Companies

Appendix

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021